Oncology – Gynecologic
Diagnostic Study | Usefulness of CT radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma
27 Jan, 2023 | 12:01h | UTC
Commentary on Twitter
Radiomic features extracted from contrast-enhanced CT scans were useful in the classification of histologic subtypes in epithelial ovarian carcinoma, high-grade serous carcinoma (HGSC) and non-HGSC. https://t.co/DBAXnl9r0X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) December 6, 2022
Meta-analysis reaffirms benefits of O-RADS MRI for diagnosing indeterminate adnexal lesions
24 Jan, 2023 | 14:05h | UTCOriginal Study: O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates – Radiology (link to abstract – $ for full-text)
Commentary on Twitter
A meta-analysis of 4520 adnexal lesions from 12 studies showed that MRI O-RADS has a 92% summary sensitivity and a 91% summary specificity in characterizing lesions that are indeterminate at US. https://t.co/WSJVQUiM4T pic.twitter.com/kssAK2s02N
— Radiology (@radiology_rsna) November 23, 2022
Review | Advances in the diagnosis and early management of gestational trophoblastic disease
19 Jan, 2023 | 14:08h | UTCAdvances in the diagnosis and early management of gestational trophoblastic disease – BMJ Medicine
Review | Human papillomavirus vaccination and cervical cancer risk.
16 Dec, 2022 | 13:26h | UTCHuman papillomavirus vaccination and cervical cancer risk – The BMJ
Review | Endometrial cancer: molecular classification and future treatments.
16 Dec, 2022 | 13:20h | UTCEndometrial cancer: molecular classification and future treatments – BMJ Medicine
Commentary on Twitter
The latest #review by Bradley Corr and colleagues concludes that the development of molecular analysis combined with novel agents and new drug classes have revolutionised #precisionmedicine for patients with endometrial #cancer. Read now ▶️ https://t.co/TaNgrM2EWl#MedTwitter pic.twitter.com/GexXdLzlQH
— BMJMedicine (@BMJMedicine) December 9, 2022
RCT | Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer.
14 Dec, 2022 | 14:44h | UTCOptimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
👍 LESS IS MORE – Extra cycles of bevacizumab in frontline maintnenance do not yield improved progression free or overall survival in advanced stage #OvarianCancer
👍 15 months remains standard of care ➡️ https://t.co/nKwehjxnHu #gyncsm pic.twitter.com/9DBInZv1t0— Journal of Clinical Oncology (@JCO_ASCO) December 4, 2022
Endocervical sampling in women with suspected cervical neoplasia: a meta-analysis of diagnostic test accuracy studies.
9 Dec, 2022 | 13:12h | UTC
German Guidelines on Sarcoma of the Uterus.
6 Dec, 2022 | 13:50h | UTCStudy | The future risk of cervical precancer among HPV–negative women is increased with a history of HPV–positive results.
1 Nov, 2022 | 12:13h | UTC
The bleeding cervical cancer patient: systematic approach and management.
26 Oct, 2022 | 14:30h | UTCThe Bleeding Cervical Cancer Patient: Systematic Approach and Management – emDocs
Secondary prevention of cervical cancer | ASCO resource–stratified guideline update.
6 Oct, 2022 | 13:44h | UTC
Systematic Review | Impact of residual disease in women with advanced epithelial ovarian cancer after primary surgery.
30 Sep, 2022 | 12:28h | UTC
ASCO Guideline Update | Poly(ADP-Ribose) Polymerase inhibitors in the management of ovarian cancer.
28 Sep, 2022 | 13:44h | UTC
Validation of the geriatric vulnerability score in older patients with ovarian cancer.
27 Sep, 2022 | 13:00h | UTC
M-A of randomized trials | Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer.
20 Sep, 2022 | 13:23h | UTCRelated:
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer – New England Journal of Medicine
Systematic Review | Debulking hysterectomy followed by chemoradiotherapy vs. chemoradiotherapy alone for women with locally advanced cancer of the cervix – not enough evidence to guide recommendations.
19 Sep, 2022 | 12:39h | UTC
Systematic Review | Ultra‐radical (extensive) surgery vs. standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
13 Sep, 2022 | 12:56h | UTCRelated Study: Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine
Screening for high-risk human papillomavirus using passive, self-collected menstrual blood.
11 Sep, 2022 | 22:41h | UTCCommentary: Pap smears, be gone? Using menstrual blood to detect HPV – Stanford Medicine
Commentary on Twitter
FREE: Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood #obgyn #HPV #GYN https://t.co/zLno2ab605 pic.twitter.com/mfPGjlTLdD
— The Green Journal (@greenjrnl) September 1, 2022
RCT | Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation.
11 Sep, 2022 | 22:21h | UTC
A simple cervicovaginal epigenetic test for screening and rapid triage of women with suspected endometrial cancer: validation in several cohort and case/control sets.
29 Aug, 2022 | 11:58h | UTC
Commentary on Twitter
Pleased to share our work out today in J Clin Oncol "A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer …" #FORECEE #CCBIO #H2020 @eveappeal @Gynkreft @medofak_uib @haukeland_no
#screening https://t.co/Av53WSWqoQ pic.twitter.com/dL4j7nW7vt— Line Bjørge (@DrLB) August 24, 2022
Under a https://creativecommons.org/licenses/by/4.0/ license
RCT | HPV self-sampling among long-term non-attenders to cervical cancer screening.
26 Aug, 2022 | 13:27h | UTC
Commentary on Twitter
Pragmatic randomised controlled trial of 3 different HPV screening approaches suggests that opt-in and particularlly send-to-all self-sampling increased participation among long-term, higher-risk non-attenders: https://t.co/hBouqoBMnU #GynCSM #hsronc
— NatureRevClinOncol (@NatRevClinOncol) August 25, 2022
Endocervical sampling in women with suspected cervical neoplasia: a systematic review and meta-analysis of diagnostic test accuracy studies.
26 Aug, 2022 | 13:18h | UTC
Systematic Review | Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
26 Aug, 2022 | 13:11h | UTC
Observational study suggests frequent aspirin use may reduce the risk of ovarian cancer.
25 Aug, 2022 | 11:49h | UTCModification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentaries:
Frequent Aspirin Use Tied to Lower Ovarian Cancer Risk – HealthDay
Commentary on Twitter
💊 Frequent aspirin use ⬇️ #OvarianCancer risk among women with other risk factors for ovarian cancer
Read more in #JCO: https://t.co/QV4bK0lB5M #prevention #gyncsm #ovca @LaurenMHurwitz @b_trabert pic.twitter.com/xvU1yb60mi
— Journal of Clinical Oncology (@JCO_ASCO) August 18, 2022
Long-term follow up of a RCT | Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine.
24 Aug, 2022 | 13:53h | UTCPrecancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Virological replacement & clinical unmasking are two phenomena of interest following #HPVvaccination. We show that clinical unmasking might attenuate long-term reductions in cervical precancer following successful implementation of HPV vax programs in highly screened populations https://t.co/Z7dGQNG1kG
— Monica Sierra (@MonicaSSierra) June 14, 2022